MedTrace Logo

Reduction of Postherpetic Neuralgia in Herpes Zoster

NCT01250561 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2010-12-01

No results posted yet for this study

Summary

The addition of gabapentin therapy to standard antiviral treatment with valacyclovir in acute herpes zoster patients will decrease the incidence of post-herpetic neuralgia.

Conditions

  • Herpes Zoster
  • Post-herpetic Neuralgia

Interventions

DRUG

Gabapentin

gabapentin 300mg/day, titrated up weekly to max tolerated dose or 3600mg/day (whichever is lower), for 4-9 weeks

DRUG

Valacyclovir

valacyclovir 1000mg three-times daily x 7 days

Sponsors & Collaborators

  • Center for Clinical Studies, Texas

    lead OTHER

Principal Investigators

  • Stephen Tyring, MD, PhD · Center for Clinical Studies

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01250561 on ClinicalTrials.gov